Natco launches cut price versions of cancer drug ibrutinib in india

The patent for the drug is held by Pharmacyclics for three to four more years in India. Pharmacyclics was globally acquired by US giant AbbVie in 2015 in a massive USD21 billion deal. Natco's latest move is consistent with its earlier launches and challenging the patents held on anti-cancer drugs by multinational drug companies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2sOQSpT
via IFTTT

0 comments:

Post a Comment